Physician profile
John M Soderberg
NPI 1386810588
$397,859.99
in general payments reported to CMS, 2019-2025
36 companies · $125K in 2025
The $125K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $315 · 2021: $1,124 · 2022: $57K · 2023: $103K · 2024: $111K · 2025: $125K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $236K · Consulting Fee: $50K · Travel and Lodging: $31K · Food and Beverage: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,220 · Education: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $235,962.00 |
| Consulting Fee | $49,905.00 |
| Travel and Lodging | $30,640.65 |
| Food and Beverage | $15,131.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,220.00 |
| Education | $440.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $102,158.38 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $59,335.62 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $45,456.20 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $43,187.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $41,789.60 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $33,300.05 | 2020-2025 | Nemluvio, Aklief, Epsolay |
| Arcutis Biotherapeutics, INC. | $28,968.46 | 2024-2025 | Zoryve |
| Incyte Corporation | $22,159.71 | 2021-2025 | Opzelura |
| Ucb, INC. | $9,389.13 | 2019-2025 | Bimzelx |
| Kowa Pharmaceuticals America, INC. | $3,697.89 | 2025 | Zoryve |
| Genzyme Corporation | $2,971.63 | 2019-2025 | |
| Abbvie INC. | $1,838.25 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $627.23 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $549.36 | 2019-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $461.23 | 2019-2025 | Cabtreo, Jublia, Arazlo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $449.92 | 2019-2025 | Adbry |
| Journey Medical Corporation | $286.14 | 2023 | |
| Novartis Pharmaceuticals Corporation | $243.50 | 2019-2025 | |
| Dermavant Sciences, INC. | $234.13 | 2023-2024 | Vtama |
| Organon LLC | $159.92 | 2025 | Vtama, Nexplanon |
| Biofrontera INC. | $80.27 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $76.89 | 2021-2022 | |
| Almirall LLC | $72.08 | 2019-2023 | Klisyri |
| Organogenesis INC. | $65.83 | 2024 | |
| Vyne Pharmaceuticals INC. | $52.47 | 2021 | |
| Botanix Sb INC | $50.40 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $49.79 | 2021-2024 | |
| Paratek Pharmaceuticals, INC. | $28.83 | 2022-2023 | Nuzyra |
| Genentech USA, INC. | $21.83 | 2023 | Xolair |
| Strata Skin Sciences, INC. | $20.54 | 2024 | Xtrac |
| Sensus Healthcare, INC. | $18.59 | 2020 | |
| Tempus Ai, INC | $18.02 | 2024 | |
| Verrica Pharmaceuticals INC. | $15.31 | 2023 | Ycanth |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Dermira, INC. | $12.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$335,826.42 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Soderberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.